Background Anti-TNFa therapies have improved response rates in inflammatory bowel
disease. However primary loss of response is problematic. Aim Aim of this study was to …

Background and Aim Anti‐tumor necrosis factor alpha (TNFα) therapies have improved
outcomes for patients with inflammatory bowel disease. The aim of this study was to explore …

Background Loss of response (LOR) is a big concern for anti-TNFa therapies in
inflammatory bowel disease. Immunomonitoring may be useful to optimize response rates …

Background: The anti-TNF drugs adalimumab (ADA) and infliximab (IFX) are effective
treatments for inflammatory bowel disease (IBD). However, 40% of patients lose response …

Infliximab (Remicade) and adalimumab (Humira), both monoclonal antibodies towards TNF-
a, are widely used in the treatment of Crohn's disease and ulcerative colitis. Loss of efficacy …

Introduction Therapeutic failures with biologic drugs in inflammatory bowel disease (IBD)
pose a significant challenge for clinicians who manage patients with IBD. There is a paucity …

Background: Anti-TNF blockers (infliximab and adalimumab) are approved and used in the
treatment of Crohn's disease (CD) and ulcerative colitis (UC). Since higher drug trough …

Background Infliximab is effective for the treatment of refractory inflammatory bowel disease
(IBD). Nevertheless, up to 40% of patients lose response to infliximab over time. The aim …

Background & Aims Few agents are available for the treatment of inflammatory bowel
diseases, and patients frequently become unresponsive to biologics. We investigated the …

The severity of the disease may play a role as this cohort consists of patients with acute
severe or moderately severe steroid-refractory UC. Overall, patients with severely active UC …